HR positive + HER-2 negative

In patients with OBC, pathologic assessment of the clipped node can reflect disease burden in the remaining ALNs. Limited axillary surgery anchored in removal of the clipped node should be considered as a strategy for axillary staging following systemic therapy in selected patients with OBC, primarily those with cN1 or cN2 disease.

One in 8 patients with HR + MBC has long-term disease control with first-line, single-agent ET. These are younger patients with good performance status, non-visceral metastases, and tumors that express PR. Further research is needed to identify tumor characteristics that predict long-term disease control with ET alone.

In patients with cN0 HR+, HER2-negative breast cancer, SLN positivity after NACT varies and is more common in high-risk subgroups of this population. Frozen section has modest sensitivity overall and is more limited for the diagnosis of low-volume nodal disease. Use of frozen section may be warranted where avoiding reoperation is a priority.

P1, N=80, Active, not recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Trial primary completion date: Dec 2025 --> Dec 2026

P3, N=3680, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

As CDK4/6is remain frontline therapy, further studies are needed to optimize treatment sequencing and improve post-CDK4/6i outcomes. Department of Defense grant (HT9425-24-1-0991) and the National Cancer Institute MDACC Support Grant (P30 CA016672).

A woman in her 50s with a history of atopic dermatitis underwent left mastectomy and sentinel lymph node biopsy for hormone receptor-positive, HER2-negative breast cancer, followed by weekly adjuvant paclitaxel chemotherapy...Empirical intravenous antibiotic therapy was initiated and later deescalated to oral tedizolid after methicillin-resistant Staphylococcus aureus was confirmed...SPE should be considered in patients with breast cancer who develop fever and new pulmonary nodules during adjuvant chemotherapy, particularly in those with underlying skin conditions or chemotherapy-induced immunosuppression. Prompt recognition and targeted antibiotic therapy are essential for achieving favorable clinical outcomes.

First-line CDK4/6 inhibitor-based therapy remains the standard of care, but a new wave of trials shifts the focus to identifying who benefits and when biology should inform treatment optimization. Incorporating biomarker-selected intensification and embedding PROs, PREMs, and quality-adjusted endpoints more closely align treatment with what patients value.

However, these findings should be interpreted with caution given the study's retrospective nature and inherent limitations. Prospective studies are needed to confirm these observations and identify patient subgroups most likely to benefit from each treatment sequence.

Kaplan-Meier analysis demonstrated that patients classified as low-risk by the model had a significantly better prognosis than those classified as high-risk, with a hazard ratio of 4.1 (P < 0.001) and 2.0 (P < 0.01) on the two external cohorts that include patient outcomes. This artificial intelligence-driven solution offers a rapid, cost-effective, and scalable alternative to genomic testing, with the potential to enhance personalized treatment planning, especially in resource-constrained settings.

Chemotherapy was the first-line regimen in 83 of 162 patients (51%), endocrine monotherapy in 55 of 162 (34%), and trastuzumab-pertuzumab-taxane or cyclin-dependent kinase 4 and 6 inhibitor-based regimens in eight of 162 (5%). 87534309); Center for Global Health at the United States-National Cancer Institute at the National Institutes of Health (contract award No. HHSN2612010000871/NO2-PC-2010-00087); Fogarty International Center, NIH, HHS; and Susan G. Komen for the Cure; in Argentina, Instituto Nacional del Cáncer (Ministry of Health), Fundación Argentina de Nanotecnología, Agencia Nacional de Promoción Científica y Tecnológica, CONICET (Ministry of Science, Technology, and Productive Innovation); Brazil, Ministério da Saúde (Ministry of Health); Chile, Instituto de Salud Pública (Public Health Institute) and Ministerio de Salud (Ministry of Health); and Mexico, Consejo Estatal de Ciencia y Tecnología de Jalisco (COECYTJAL) and Universidad de Sonora (University of Sonora).

P2, N=30, Recruiting, Massachusetts General Hospital | Trial completion date: Mar 2027 --> Apr 2028 | Trial primary completion date: Aug 2026 --> Mar 2027